Madrigal Pharmaceuticals, Inc. (MDGL) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

20/25

Growth 5 Margin 5 Expansion 3 Platform 3 Financial 4

latest quarter score

Earnings Reports

20
Madrigal Pharmaceuticals (MDGL) Q2 2026: ResDifera Patient Base Doubles, Underpinning $1.3B Trailing Sales Run-Rate
July 30, 2026
14
Madrigal Pharmaceuticals (MDGL) Q1 2026: ResDifera Patient Base Up 2.5x, Pipeline Expansion Accelerates MASH Leadership
May 06, 2026
21
Madrigal Pharmaceuticals (MDGL) Q4 2025: U.S. MASH Diagnosed Population Expands 50%, Extending Market Runway
February 23, 2026
20
Madrigal Pharmaceuticals (MDGL) Q3 2025: ResDifera Patient Base Jumps 28%, Secures Path to $1B+ Specialty Franchise
November 04, 2025
14
Madrigal Pharmaceuticals (MDGL) Q2 2025: ResDifera Run Rate Tops $800M as Patent Extension Secures Decade-Long Growth Runway
August 05, 2025
16
Madrigal Pharmaceuticals (MDGL) Q1 2025: 17,000+ Patients on ResDifera Signals Durable Specialty Launch Trajectory
July 04, 2025

Browse all companies